Sleep and orexin: A new paradigm for understanding behavioural-variant frontotemporal dementia?
Behavioural-variant frontotemporal dementia
Pathophysiology
Sleep
orexin
Journal
Sleep medicine reviews
ISSN: 1532-2955
Titre abrégé: Sleep Med Rev
Pays: England
ID NLM: 9804678
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
10
03
2020
revised:
12
05
2020
accepted:
15
05
2020
pubmed:
4
8
2020
medline:
5
10
2021
entrez:
4
8
2020
Statut:
ppublish
Résumé
Behavioural variant frontotemporal dementia (bvFTD) is a complex and heterogeneous disorder with as yet unidentified unifying pathophysiological mechanism. There is emerging evidence that hypothalamic dysfunction, manifesting as disturbances in sleep and metabolism, is an integral component of neurodegeneration in bvFTD. Although sleep and metabolic disturbances and the behavioural abnormalities of bvFTD may appear disparate on the surface, there may be a common underlying hormonal mechanism involving orexin. Orexin is a hypothalamic neurotransmitter directly responsible for control of sleep and metabolism in healthy individuals and is implicated in many abnormal behaviours commonly seen in bvFTD - such as impulsive behaviour, hedonistic reinforcement and binge-consumption of ethanol. Further characterising orexin's role in pathophysiology of bvFTD could lead to a new paradigm for understanding this disease and may provide a new direction towards effective management and treatment.
Identifiants
pubmed: 32745956
pii: S1087-0792(20)30104-0
doi: 10.1016/j.smrv.2020.101361
pii:
doi:
Substances chimiques
Orexins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101361Informations de copyright
Crown Copyright © 2020. Published by Elsevier Ltd. All rights reserved.